이엔셀

456070KOSDAQ기초 의약물질 제조업

46.2 / 100

Reference Date: 2026-06-10

Financial Score10.0 / 40

News Sentiment20.2 / 25

Momentum4.0 / 20

Disclosure12.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Plunged 38.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

InCell operates two business models based on its GMP technology for cell and gene therapy drug development: CDMO (Contract Development and Manufacturing Organization) for advanced biopharmaceuticals and the development of next-generation cell and gene therapy drugs. The company holds the only GMP facility in South Korea capable of simultaneous cell and virus production, focusing on therapies for rare diseases like Charcot-Marie-Tooth and Duchenne muscular dystrophy.

Number of Employees

112people

Average Salary

42.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

2.46Industry Average 1.742.5Point

Higher than industry avg (caution)

ROE

-36.79Industry Average -6.033.5Point

6.1x industry avg (excellent)

Debt Ratio

53.53Industry Average 6.620.0Point

8.1x industry avg (risky)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼27.1% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼14.2% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -36.0% (declining, 2yr)

Detailed News Sentiment

8 totalPositive 7Neutral 1Negative 0Average Sentiment Score 80.6

Positive
이엔셀, 美 안델린과 맞손…북미·아시아 CGT CDMO 시장 공략
이엔셀이 미국 기업과의 파트너십을 통해 북미와 아시아 CGT CDMO 시장 진출을 확대함으로써 긍정적인 성장 전망을 보임.
Positive
이엔셀, 인게니움 NK세포치료제 美 임상용 추가 수주…글로벌 CDMO ...
이엔셀이 NK세포치료제 미국 임상용 추가 수주로 글로벌 공급망 확장에 성공했다.
Positive
이엔셀, 인게니움과 NK세포치료제 CDMO 계약…日시장 확장 본격화
이엔셀이 인게니움과의 계약으로 일본 시장 진출 가속화, 긍정적 전망.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 8,790Won52-week high 20,15052-week low 8,790

1-month return0.0Point

1m -38.79% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 1Neutral 3Negative 0

Neutral기업설명회(IR)개최2026-06-02
Positive[기재정정]단일판매ㆍ공급계약체결2026-06-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-20
Neutral분기보고서 (2026.03)2026-05-15